Q-omics provides the consensus-scored BCO2 profile across patient tissues and cancer cell-line models. BCO2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCO2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, BCO2 RNA expression shows 17,967 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where BCO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCO2 survival associations across molecular data types. BCO2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCO2 RNA expression–survival associations across cancer types. High BCO2 expression shows unfavorable associations in KIRC and LGG, but favorable associations in SKCM, ACC, HNSC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCO2 RNA expression.
This table summarizes BCO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BCO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCO2 shows lower tumor expression in BLCA, THCA, LIHC and LUAD and higher tumor expression in KIRP and KICH. The BLCA box plot shows higher BCO2 RNA expression in normal versus tumor tissue (log2 FC = −1.243, t-test p < 0.001).
This table shows molecular features associated with BCO2 in patient tissues and cancer cell lines. In patient samples, BCO2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
